METALYSE 6000U 5mg / ml (1000U / ml) powder + solvent for injection medication leaflet

B01AD11 tenecteplaza • Blood and blood forming organs | Antithrombotic agents | Enzymes

Tenecteplase is a medication used to treat acute myocardial infarction (heart attack), particularly in cases where rapid intervention is needed to restore blood flow to the heart. It belongs to the class of thrombolytic (fibrinolytic) drugs and works by dissolving blood clots that block coronary arteries.

Tenecteplase is administered via intravenous injection, usually as a single dose, as soon as possible after the onset of heart attack symptoms. It is preferred in some cases due to its rapid administration and lower risk of bleeding compared to other thrombolytics.

Common side effects include nausea, vomiting, low blood pressure, and injection site reactions. A major risk associated with tenecteplase is bleeding, including intracranial hemorrhage, which can be severe or even fatal. Therefore, the medication is contraindicated in patients with a high risk of bleeding, such as those with a history of hemorrhagic stroke or active gastrointestinal ulcers.

Tenecteplase is used under strict medical supervision, typically in intensive care or emergency settings. It is essential that administration is performed by qualified medical personnel, and patients are closely monitored to prevent and manage potential complications.

General data about METALYSE 6000U 5mg / ml (1000U / ml)

Substance: tenecteplaza

Date of last drug list: 01-07-2013

Commercial code: W13567001

Concentration: 5mg / ml (1000U / ml)

Pharmaceutical form: powder + solvent for injection

Quantity: 1

Product type: original

Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.

Marketing authorisation

Manufacturer: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG - GERMANIA

Holder: BOEHRINGER INGELHEIM INTERNATIONAL GMBH - GERMANIA

Number: 169/2002/01

Shelf life: 2 years

Pharmaceutical forms available for tenecteplaza